Nanocarrier mediated co-delivery of phytochemicals and chemo-drugs: an emerging strategy to combat lung cancer in a systemic way

Upadhyay, Priyanka; Ghosh, Avijit; Sarangthem, Vijaya; Singh, Thoudam Debraj

doi:10.1007/s11101-023-09894-9

Cited by 3 publications

(2 citation statements)

References 218 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rapid progression and development of chemotherapy resistance in ES-SCLC remain substantial challenges in oncology 34 . Our study takes a novel approach by introducing anlotinib in first-line treatment, providing a potential avenue to enhance outcomes in ES-SCLC patients.…”

Section: Discussionmentioning

confidence: 99%

The Efficacy and Safety of Anlotinib Plus Etoposide with Cisplatin/Carboplatin in the First-Line Treatment of Lung Cancer: A Phase II Clinical Study

Lv,

Liu,

Feng

et al. 2024

J. Cancer

View full text Add to dashboard Cite

Background: The primary aim of this phase II clinical study was to assess the safety and efficacy of combining anlotinib, etoposide, and platinum-based drugs as a first-line treatment for ES-SCLC. Methods: Patients underwent the standard chemotherapeutic regimen, consisting of four courses of etoposide plus cisplatin/carboplatin. Additionally, each patient received a 2-week intervention with anlotinib (12 mg/day, once daily). Anlotinib was continued until disease progression, occurrence of unbearable adverse events (AEs), or withdrawal from the research. Progression-free survival (PFS) served as the primary prognostic measure. Secondary measures included the disease control rate (DCR), objective response rate (ORR), overall survival time (OS), and the incidence of AEs. Results: The DCR and ORR were 97.6% and 91.0%, respectively. Estimated PFS and OS were 5.0 months (95% CI: 1.0-10.8 months) and 13.0 months (95% CI: 8.4-18.6 months), respectively. No unexpected adverse effects were reported during the trial. The most common adverse reactions included anemia (42.22%), hypertension (53.33%), alopecia (40.00%), elevated transaminase (24.40%), and elevated alkaline phosphatase (24.44%). Sixteen cases (35.56%) were classified as AEs of grades 3-5. No deaths attributed to treatment-related causes occurred in any patient during the trial. Conclusion: Combination chemotherapy is currently the first-line therapy for extensive small-cell lung cancer (ES-SCLC). Combining anlotinib with conventional platinum-based chemotherapy demonstrated promising therapeutic outcomes and prognosis in the management of ES-SCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

The Efficacy and Safety of Anlotinib Plus Etoposide with Cisplatin/Carboplatin in the First-Line Treatment of Lung Cancer: A Phase II Clinical Study

Lv,

Liu,

Feng

et al. 2024

J. Cancer

View full text Add to dashboard Cite

show abstract

“…Moreover, organosulfur polymers can potentially encapsulate many drugs, including hydrophobic and hydrophilic compounds especially with thiol (-SH) or sulfide (-S-) which are interacted strongly through covalent or non-covalent interactions [42]. These interactions permit efficient drug loading and encapsulation in the polymer matrix.…”

Section: Properties Of Organosulfur-based Polymersmentioning

confidence: 99%

Advances in Organosulfur-Based Polymers for Drug Delivery Systems

Islam,

Zeng

2024

Polymers

View full text Add to dashboard Cite

Organosulfur-based polymers have unique properties that make them useful for targeted and managed drug delivery, which can improve therapy while reducing side effects. This work aims to provide a brief review of the synthesis strategies, characterization techniques, and packages of organosulfur-based polymers in drug delivery. More importantly, this work discusses the characterization, biocompatibility, controlled release, nanotechnology, and targeted therapeutic aspects of these important structural units. This review provides not only a good comprehension of organosulfur-based polymers but also an insightful discussion of potential future prospectives in research. The discovery of novel organosulfur polymers and innovations is highly expected to be stimulated in order to synthesize polymer prototypes with increased functional accuracy, efficiency, and low cost for many industrial applications.

show abstract

Empowering lung cancer treatment: Harnessing the potential of natural phytoconstituent‐loaded nanoparticles

Siddiquee,

Bhaskaran,

Nathani

et al. 2024

Phytotherapy Research

View full text Add to dashboard Cite

Lung cancer, the second leading cause of cancer‐related deaths, accounts for a substantial portion, representing 18.4% of all cancer fatalities. Despite advances in treatment modalities such as chemotherapy, surgery, and immunotherapy, significant challenges persist, including chemoresistance, non‐specific targeting, and adverse effects. Consequently, there is an urgent need for innovative therapeutic approaches to overcome these limitations. Natural compounds, particularly phytoconstituents, have emerged as promising candidates due to their potent anticancer properties and relatively low incidence of adverse effects compared to conventional treatments. However, inherent challenges such as poor solubility, rapid metabolism, and enzymatic degradation hinder their clinical utility. To address these obstacles, researchers have increasingly turned to nanotechnology‐based drug delivery systems (DDS). Nanocarriers offer several advantages, including enhanced drug stability, prolonged circulation time, and targeted delivery to tumor sites, thereby minimizing off‐target effects. By encapsulating phytoconstituents within nanocarriers, researchers aim to optimize their bioavailability and therapeutic efficacy while reducing systemic toxicity. Moreover, the integration of nanotechnology with phytoconstituents allows for a nuanced understanding of the intricate molecular pathways involved in lung cancer pathogenesis. This integrated approach holds promise for modulating key cellular processes implicated in tumor growth and progression. Additionally, by leveraging the synergistic effects of phytoconstituents and nanocarriers, researchers seek to develop tailored therapeutic strategies that maximize efficacy while minimizing adverse effects. In conclusion, the integration of phytoconstituents with nanocarriers represents a promising avenue for advancing lung cancer treatment. This synergistic approach has the potential to revolutionize current therapeutic paradigms by offering targeted, efficient, and minimally toxic interventions. Continued research in this field holds the promise of improving patient outcomes and addressing unmet clinical needs in lung cancer management.

show abstract

Nanocarrier mediated co-delivery of phytochemicals and chemo-drugs: an emerging strategy to combat lung cancer in a systemic way

Cited by 3 publications

References 218 publications

The Efficacy and Safety of Anlotinib Plus Etoposide with Cisplatin/Carboplatin in the First-Line Treatment of Lung Cancer: A Phase II Clinical Study

The Efficacy and Safety of Anlotinib Plus Etoposide with Cisplatin/Carboplatin in the First-Line Treatment of Lung Cancer: A Phase II Clinical Study

Advances in Organosulfur-Based Polymers for Drug Delivery Systems

Empowering lung cancer treatment: Harnessing the potential of natural phytoconstituent‐loaded nanoparticles

Contact Info

Product

Resources

About